Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of “Buy” from Analysts

Posted by Geri Gentry on Sep 8th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) has earned a consensus recommendation of “Buy” from the twenty research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $310.05.

Several brokerages have commented on ASND. Stifel Nicolaus decreased their price target on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Wedbush reiterated an “outperform” rating and issued a $327.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. BMO Capital Markets started coverage on Ascendis Pharma A/S in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $319.00 price objective on the stock. Oppenheimer boosted their target price on Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 1st. Finally, Morgan Stanley cut their price target on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a report on Tuesday, September 1st.

View Our Latest Stock Analysis on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $270.56 on Tuesday. The stock has a market capitalization of $16.88 billion, a price-to-earnings ratio of 20.99 and a beta of 0.35. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The business has a 50-day moving average of $257.98 and a 200 day moving average of $241.19. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post 5.15 earnings per share for the current year.

Insider Activity at Ascendis Pharma A/S

In related news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares in the company, valued at $714,357. This represents a 222.22% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC purchased a new position in Ascendis Pharma A/S in the third quarter valued at $26,000. Arax Advisory Partners lifted its holdings in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares during the last quarter. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth about $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth about $42,000. Finally, Global Retirement Partners LLC increased its holdings in shares of Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares during the last quarter.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.